Skip to main content

Clinical Approach to ARVC

 


Clinical Approach to ARVC

✅ECG features of Arrhythmogenic Right Ventricular Dysplasia (ARVD) with:

πŸ”Ή TWI in precordial leads, in absence of RBBB.

πŸ”Ή Epsilon wave (most specific finding).

πŸ”Ή Localised widened QRS in V1-V3 (due to delayed RV activation).


ARVD:

- Genetic disorder of fibrofatty infiltration of myocardium. 


- Most common symptoms are palpitations/ syncope during exercise. 


- VT with LBBB pattern can become VF, usually triggered by adrenergic stimulation (e.g. exercise).




Arrhythmogenic Right Ventricular Dysplasia (ARVD), also termed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), is an inherited myocardial disease characterized by progressive fibrofatty replacement of right ventricular myocardium, leading to ventricular arrhythmias and sudden cardiac death, particularly in young individuals and athletes.



---


Definition and Pathophysiology


ARVD is a genetic cardiomyopathy, most commonly inherited in an autosomal dominant pattern. It primarily involves mutations in desmosomal proteins (plakophilin-2, desmoglein-2, desmocollin-2, desmoplakin), resulting in impaired cell-to-cell adhesion.


Loss of myocardial integrity leads to:


Myocyte detachment


Cell death


Replacement with fibrofatty tissue

This process predominantly affects the right ventricle, especially the inflow tract, outflow tract, and apex (“triangle of dysplasia”), causing delayed conduction and arrhythmogenesis.




---


ECG Features of ARVD


Electrocardiogram abnormalities are central to diagnosis and often precede structural changes.


1. T-Wave Inversion (TWI)


Present in right precordial leads (V1–V3)


Occurs in the absence of complete RBBB


Reflects abnormal repolarization due to RV myocardial disease


More significant in adults (>14 years)



2. Epsilon Wave (Most Specific Finding)


Small, low-amplitude deflection at the end of QRS complex, best seen in V1–V3


Represents delayed activation of diseased RV myocardium


Often subtle and may require signal-averaged ECG or high-gain recording



3. Localized QRS Widening (V1–V3)


QRS duration prolonged in right precordial leads compared with left leads


Caused by slow conduction through fibrofatty RV tissue


Sometimes described as terminal activation delay ≥55 ms



Other ECG Findings


Low QRS voltage


Fragmented QRS complexes


Ventricular ectopics with LBBB morphology




---


Clinical Presentation


ARVD commonly presents in young adults or athletes, often during exertion.


Common Symptoms


Palpitations


Syncope or presyncope (especially during exercise)


Sudden cardiac death as first manifestation in some cases



Ventricular Arrhythmias


Ventricular tachycardia with LBBB morphology (originating from RV)


VT may degenerate into ventricular fibrillation


Arrhythmias are often adrenergically triggered (exercise, emotional stress)




---


Diagnosis


Diagnosis is based on Revised Task Force Criteria, incorporating:


ECG abnormalities


Ventricular arrhythmias


Imaging (echo, cardiac MRI)


Histopathology


Family history and genetics



Cardiac MRI is particularly useful to demonstrate:


RV dilation or dysfunction


Fibrofatty infiltration


Late gadolinium enhancement




---


Management


Lifestyle


Strict avoidance of competitive sports and strenuous exercise



Medical Therapy


Beta-blockers


Antiarrhythmic drugs (e.g. sotalol, amiodarone)



Device Therapy


Implantable cardioverter-defibrillator (ICD) for:


Sustained VT


Syncope with high-risk features


Survivors of cardiac arrest




Catheter Ablation


For recurrent VT, usually adjunctive, not curative




---


Prognosis


ARVD is a progressive disease with variable expression. Early diagnosis and exercise restriction significantly reduce arrhythmic risk. Sudden cardiac death remains the major cause of mortality, especially in undiagnosed young individuals.



---


Key Takeaway


ARVD should be suspected in young patients with exertional syncope or VT with LBBB morphology. Epsilon waves, T-wave inversion in V1–V3 without RBBB, and localized QRS widening are hallmark ECG clues that should prompt further evaluation.


For more cardiology articles and ECG infographics, visit: drmusmanjaved.com


Comments

Popular posts from this blog

STEMI ECG Criteria and Universal Definition of MI

  STEMI ECG Criteria and the Universal Definition of Myocardial Infarction: A Complete Guide for Clinicians Early and accurate diagnosis of acute myocardial infarction (AMI) remains the cornerstone of reducing morbidity and mortality in patients presenting with chest pain. Among all forms of acute coronary syndromes (ACS), ST-elevation myocardial infarction (STEMI) represents the most time-sensitive emergency, requiring immediate reperfusion therapy. This article provides a clinically relevant summary of the STEMI ECG criteria and the Universal Definition of Myocardial Infarction (UDMI), based on the latest consensus guidelines from the ESC, ACC, AHA, and WHF. --- 1. Understanding STEMI: Why Accurate ECG Interpretation Matters A 12-lead ECG remains the first and most critical diagnostic test when evaluating suspected myocardial infarction. STEMI is identified when there is evidence of acute coronary artery occlusion, producing transmural ischemia and characteristic ST-segment eleva...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...